| Li, Lei |
EVALUATE-STEMI, NCT05613426: Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI |
|
|
| Recruiting | 4 | 330 | RoW | Rosuvastatin 20 mg, Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA] | Henan Institute of Cardiovascular Epidemiology | ST Elevation Myocardial Infarction (STEMI) | 12/25 | 12/26 | | |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
| Recruiting | 3 | 556 | RoW | long-acting granulocyte colony stimulating factor, polyethylene glycol granulocyte colony stimulating factor, Short-term granulocyte colony stimulating factor | Lei Li | Epithelial Ovarian Cancer, Colony Stimulating Factors, Febrile Neutropenia, Myelosuppression Adult, Adverse Event, Cost-effectiveness | 11/19 | 11/23 | | |
NCT03739944: Different Surgical Approaches in Patients of Early-stage Cervical Cancer |
|
|
| Recruiting | 3 | 700 | RoW | Laparotomic radical hysterectomy, Laparotomic radical trachelectomy, Laparoscopic radical hysterectomy, Laparoscopic radical trachelectomy | Lei Li | Uterine Cervical Neoplasm, Laparotomy, Laparoscopy, Survival, Mortality, Morbidity, Quality of Life, Pelvic Floor Disorders, Cost-Benefit Analysis | 11/22 | 11/23 | | |
NCT04646954: DNA Methylation Testing for the Screening of Uterine Cervical Lesion |
|
|
| Recruiting | 3 | 12000 | RoW | Host DNA methylation testing, Cervical cytology and/or high-risk human papillomavirus assays | Lei Li | Cervical Cancer, Cervical Intraepithelial Neoplasia, DNA Methylation, High-risk Human Papillomavirus, Cytology | 11/22 | 11/22 | | |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
NCT04370925: Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis |
|
|
| Recruiting | 3 | 688 | RoW | Radical colectomy, HIPEC, Systemic chemotherapy | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University | Colorectal Cancer | 04/24 | 04/26 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C |
|
|
| Recruiting | 2/3 | 520 | RoW | HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo | Sunshine Lake Pharma Co., Ltd. | Chronic HCV Infection | 04/23 | 04/23 | | |
NCT04650711: Immunohistochemical Staining of p16 for the Screening of Cervical Cancer |
|
|
| Recruiting | 2 | 250 | RoW | p16 protein expression, p16INK4A immunohistochemical staining | Lei Li | Cervical Cancer Screening, p16 Protein, Cytology, High-risk Human Papillomavirus, Diagnostic Accuracy, Histology, Cervical Intraepithelial Neoplasia | 11/20 | 11/20 | | |
NCT04635956: Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas |
|
|
| Recruiting | 2 | 20 | RoW | Drug therapy | Lei Li | Chemotherapy, Anti-pd-1 Antibody, Cervical Neuroendocrine Carcinoma, Adverse Drug Event, Recurrent Cervical Carcinoma, Advanced Cervical Carcinoma, Objective Response Rate | 11/21 | 11/21 | | |
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer |
|
|
| Recruiting | 2 | 58 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 06/22 | 09/22 | | |
NCT04651946: Cell-free DNA Methylation for Epithelial Ovarian Cancer |
|
|
| Recruiting | 2 | 400 | RoW | DNA methylation testing | Lei Li | Epithelial Ovarian Cancer, DNA Methylation, Benign Ovarian Tumor, Training Set, Validation Set, Cell-free DNA, Liquid Biopsy | 11/22 | 11/22 | | |
REPACC-3, NCT05290935: Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial |
|
|
| Recruiting | 2 | 122 | RoW | Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel | Lei Li | Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Immune Checkpoint Inhibitors, Anti-PD-1 Antibody, Albumin-bound Paclitaxel | 12/22 | 03/24 | | |
NCT05311579: Niraparib Plus Anlotinib for Recurrent Ovarian Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Niraparib plus anlotinib | Lei Li | Ovarian Carcinoma, Survival Outcomes, Adverse Events, Niraparib, Anlotinib, CA125, Chemotherapy, Targeted Therapy, Recurrent Ovarian Cancer | 03/23 | 03/24 | | |
NCT05310344: Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Albumin-bound paclitaxel and bevacizumab | Lei Li | Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma, Albumin-bound Paclitaxel, Bevacizumab, Survival Outcomes, Adverse Events | 03/23 | 03/24 | | |
NCT05310383: Tislelizumab and Radiotherapy for Recurrent Cervical Cancer |
|
|
| Recruiting | 2 | 58 | RoW | Tislelizumab plus radiotherapy | Lei Li | Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma, Radiotherapy, Immunotherapy, Anti-programmed Cell Death Receptor 1, Immune Checkpoint Inhibitors, Tislelizumab, Objective Response Rate, Survival Outcomes | 03/23 | 03/24 | | |
NCT05311566: PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer |
|
|
| Recruiting | 2 | 92 | RoW | Camrelizumab plus Concurrent chemoradiotherapy | Lei Li | Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy, Immune Checkpoint Inhibitor, Survival Outcomes, Adverse Events, Early Stage Cervical Cancer, Locally Advanced Cervical Cancer | 03/23 | 03/26 | | |
| Recruiting | 2 | 20 | RoW | Donafenib combined with paclitaxel and platinum ± PD-1 antibody | Lei Li | Targeted Therapy, Chemotherapy, Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Survival Outcomes, Adverse Effect | 12/23 | 06/24 | | |
NCT04664244: Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | Combination of nimotuzumab and radiotherapy | Lei Li | Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor, Nimotuzumab, Objective Response Rate, Progression-free Survival, Overall Survival | 12/23 | 12/23 | | |
| Recruiting | 2 | 60 | RoW | Two cycles of neoadjuvant chemotherapy, First imaging evaluation, Second imaging evaluation, The third cycles of neoadjuvant chemotherapy, RH, Radiochemotherapy, Pathologic evaluation | Lei Li | Neoadjuvant Chemotherapy, Locally Advanced Cervical Cancer, Radical Hysterectomy, Objective Response, Laparoscopy, Laparotomy, Concurrent Chemoradiotherapy, Adjuvant Therapy, Systematic Chemotherapy | 06/24 | 06/25 | | |
NCT05632861: HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) |
|
|
| Recruiting | 2 | 76 | RoW | HuHuangLianzonggan capsule, Experimental group, HuHuangLianzonggan capsule placebo, Placebo group | Tasly Pharmaceutical Group Co., Ltd | NASH | 12/24 | 12/24 | | |
NCT06063018: RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer |
|
|
| Recruiting | 2 | 30 | RoW | RC48 + Tislelizumab | Peking Union Medical College Hospital | Cervical Cancer Recurrent | 08/25 | 08/26 | | |
NCT06378242: To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 |
|
|
| Recruiting | 1/2 | 24 | RoW | Disitamab Vedotin for injection, RC48 | RemeGen Co., Ltd. | High-risk Non-muscle Invasive Bladder Cancer | 03/29 | 12/29 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT04121520: Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey |
|
|
| Completed | N/A | 200 | Europe, Japan, RoW | Questionnaire | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Shandong Provincial Hospital, Xingtai People's Hospital, Zhejiang University, Ankara University, Chiba University Graduate School of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, S. Orsola-Malpighi Hospital, University of Bologna, Universidade Federal de Pernambuco, Hanyang University College of Medicine | Portal Hypertension, Cirrhosis, Liver | 08/21 | 08/22 | | |
NCT04190667: Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer |
|
|
| Recruiting | N/A | 1300 | RoW | Genomic testing | Lei Li | Epithelial Ovarian Cancer, Chinese, Homologous Recombination Deficiency, BRCA1 Mutation, BRCA2 Mutation, Prognosis | 12/21 | 12/22 | | |
NCT03291262: Survival Outcomes of Ovarian Malignancies in Chinese Population |
|
|
| Recruiting | N/A | 5000 | RoW | Follow up for death and recurrence | Lei Li | Ovarian Neoplasms, Survival | 01/22 | 01/23 | | |
NCT03291236: Survival Outcomes of Uterine Cervical Malignancies in Chinese Population |
|
|
| Recruiting | N/A | 5000 | RoW | Follow-up for death and recurrence of patients | Lei Li | Uterine Cervical Neoplasms, Survival | 01/22 | 01/23 | | |
| Recruiting | N/A | 300 | RoW | Multi-gene panel testing | Lei Li | Recurrent Cervical Cancer, Nucleotide Variant, Copy Number Variation, Insertion-deletion Variation, Genomic Structural Variation, Total Mutation Burden, Microsatellite Instability, PD-1, PD-L1 | 01/22 | 01/23 | | |
| Recruiting | N/A | 500 | RoW | A multi-gene panel testing | Lei Li | Epithelial Ovarian Cancer, Nucleotide Variant, Copy Number Variation, Insertion-deletion Variation, Genomic Structural Variation, Total Mutation Burden, Microsatellite Instability, PD-1, PD-L1 | 01/22 | 01/23 | | |
NCT03967457: Comprehensive Study on the Quality of Life in Cervical Cancer Patients |
|
|
| Recruiting | N/A | 10000 | RoW | questionnaires survey, Urodynamic testing, Rectum dynamics testing, ovarian reserve function | Lei Li | Quality of Life, Cervical Cancer, Urodynamics, Rectum Dynamics, Sex Dysfunction, Pelvic Floor Disorders, Ovarian Reserve Function, Survivorship, Disease-free Survival, Overall Survival | 06/22 | 06/23 | | |
NCT03294343: Risk-Reducing Surgeries for Hereditary Ovarian Cancer |
|
|
| Recruiting | N/A | 600 | RoW | salpingo-oophorectomy only by laparoscopy, salpingo-oophorectomy with hysterectomy by laparoscopy, Follow-up | Lei Li | Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovariectomy, Hysterectomy | 09/22 | 09/23 | | |
NCT03291275: Survival Outcomes of Uterine Malignancies in Chinese Population |
|
|
| Recruiting | N/A | 10000 | RoW | Follow-up for death and recurrence | Lei Li | Endometrial Neoplasms, Survival | 09/22 | 09/23 | | |
NCT05310305: PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer |
|
|
| Recruiting | N/A | 20 | RoW | Radiotherapy for targeted lesions and PD-1 antibody | Lei Li | Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody, Radiotherapy, Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Objective Remission Rate, Progression-free Survival, Overall Survival, Severe Adverse Events | 09/22 | 03/23 | | |
| Recruiting | N/A | 200 | RoW | Homologous recombination deficiency model | Lei Li | Epithelial Ovarian Cancer, BRCA Mutation, Loss of Heterozygosity, Prognosis, Platinum Resistance, Homologous Recombination Deficiency | 11/22 | 11/22 | | |
NCT03738969: Longitudinal Study of Different Surgical Approaches in Chinese Patients of Uterine Cervical Cancer |
|
|
| Recruiting | N/A | 3000 | RoW | Laparotomic radical hysterectomy, Laparoscopic radical hysterectomy | Lei Li | Uterine Cervical Neoplasms, Laparotomy, Laparoscopy, Survival, Mortality, Recurrence | 12/22 | 12/23 | | |
NCT05312190: Clinical and Basic Researches Related to ZhenQi Buxue Oral Liquid in Treating Menstrual Disorders |
|
|
| Recruiting | N/A | 330 | RoW | ZhenQi BuXue KouFuYe, Progesterone Capsules | Peking Union Medical College Hospital, Sichuan University West China Second University Hospital, Chongqing Medical University No.1 Affiliated Hospital, The Second Hospital of Hebei Medical University, Second Affiliated Hospital of Nanchang University, Southeast University Affiliated Zhongda Hospital, Hubei Maternal and Child Health Hospital, Liuzhou Maternity and Child Healthcare Hospital, Zhejiang University Medical College Affiliated Hangzhou First People's Hospital, Guangzhou Women and Children's Medical Center | Menstrual Disorders | 12/22 | 06/23 | | |
NCT04651738: Cell-free DNA Methylation for Endometrial Cancer |
|
|
| Recruiting | N/A | 400 | RoW | DNA methylation testing | Lei Li | Endometrial Cancer, Liquid Biopsy, DNA Methylation, Cervical Cytology, Diagnostic Accuracy, Training Set, Validation Set | 01/23 | 01/23 | | |
| Recruiting | N/A | 1400 | RoW | Methylation assay | Lei Li | Epithelial Ovarian Cancer, Circulating Tumor DNA, DNA Methylation, Non-invasive Diagnosis, CA125, Human Epididymis Protein 4, ROMA Index, Imaging Evaluation, Survival Prognosis | 03/24 | 03/26 | | |
| Recruiting | N/A | 5000 | RoW | CDO1 and HOXA9 methylation assay | Lei Li | Epithelial Ovarian Cancer, Circulating Tumor DNA, DNA Methylation, Non-invasive Diagnosis, CA125, Human Epididymis Protein 4, Imaging Evaluation, Survival Prognosis | 03/24 | 03/26 | | |
NCT06725212: Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia |
|
|
| Recruiting | N/A | 126 | RoW | Water Vapor Thermal Ablation, Water Vapor Ablation, Cystoscopy | Medtecx Co Ltd. | Benign Prostatic Hyperplasia | 06/25 | 06/26 | | |
NCT06557954: Cervical Cytology DNA Methylation for Cervical Cancer Screening |
|
|
| Not yet recruiting | N/A | 30000 | RoW | human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m), HPV testing, cytological pathology | Lei Li | Cervical Cancer, DNA Methylation, Cytology, Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia, Cancer Screening | 10/26 | 10/26 | | |
NCT06558019: Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence |
|
|
| Not yet recruiting | N/A | 509 | RoW | | Lei Li | Ovarian Cancer | 12/26 | 12/26 | | |
NCT06631495: All-cause and Diseases-specific Mortality of High-risk HPV Infection |
|
|
| Not yet recruiting | N/A | 100000 | RoW | Observation | Peking Union Medical College Hospital | HPV Infection | 10/26 | 10/27 | | |
| Recruiting | N/A | 240 | RoW | Carvedilol 12.5 MG, Nucleos(t)ide Analogues | Beijing Friendship Hospital | Liver Cirrhosis, Portal Hypertension | 10/24 | 10/24 | | |
NCT05812482: Treatment of Urethral Stricture With Urethral Drug Ball |
|
|
| Recruiting | N/A | 150 | RoW | Drug balloon dilatation, Direct vision internal urethrotomy (DVIU) | Lepu Medical Technology (Beijing) Co., Ltd. | Urethral Stricture Less Than 2 cm | 10/24 | 02/25 | | |
NCT04724148: Impact of Fentanyl Analgesia on the Accuracy of HVPG Measurements in Patients With Portal Hypertension |
|
|
| Recruiting | N/A | 4 | RoW | Fentanyl | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Lishui hospital of Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Zhejiang University | Liver Cirrhosis, Portal Hypertension, Pain | 11/24 | 11/24 | | |
NCT05931055: The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer |
|
|
| Not yet recruiting | N/A | 1000 | NA | Fragmentomics | Peking Union Medical College Hospital | Ovarian Cancer, Differentiating, Diagnosis | 01/29 | 01/32 | | |
NCT05937178: Real-world Study Optimizing Nucleotide-analogues |
|
|
| Recruiting | N/A | 20000 | RoW | ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF | Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital | Hepatitis B, Chronic | 01/29 | 01/29 | | |
| Recruiting | N/A | 6000 | RoW | Questionnaire survey | Lei Li | Workplace Violence Against Physicians, National Survey, Obstetrics and Gynecology, China, Random Sample, Questionnaire | 09/20 | 09/20 | | |
| Recruiting | N/A | 6000 | RoW | Customized questionnaire | Lei Li | COVID-19 Pandemics, Obstetrics and Gynecology, Workload, Questionnaire, National Survey, China | 09/20 | 09/20 | | |
NCT04962763: Correlation of Intestinal Flora and Metabolomics in Patients With Ischemic Heart Failure |
|
|
| Recruiting | N/A | 200 | RoW | | Peking University Third Hospital | To Search for Biomarkers Associated With Ischemic Heart Failure, To Explore the Relationship Between Intestinal Flora and Ischemic Heart Failure | 05/22 | 04/23 | | |
NCT05290415: Host DNA Methylation for Endometrial Cancer Screening |
|
|
| Recruiting | N/A | 10000 | RoW | DNA methylation testing | Lei Li, Beijing Qiyuanjuhe Biotechnology Co., Ltd | Cancer Screening, Endometrial Cancer, DNA Methylation, Cervical Cytology, Liquid Biopsy, Cohort Study | 06/22 | 09/22 | | |
NCT05290428: DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening |
|
|
| Recruiting | N/A | 459 | RoW | DNA methylation testing | Peking Union Medical College Hospital, Zhejiang Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University | Cervical Cancer, Cervical Intraepithelial Neoplasia, DNA Methylation, Cancer Screening, Detection Accuracy | 09/22 | 12/22 | | |
NCT05290922: DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening |
|
|
| Recruiting | N/A | 7150 | RoW | DNA methylation testing | Lei Li, Obstetrics & Gynecology Hospital of Fudan University, The Third Xiangya Hospital of Central South University, Women's Hospital School Of Medicine Zhejiang University | Endometrial Cancer, Cancer Screening, DNA Methylation, Testing Accuracy, Cervical Cytology | 09/22 | 03/23 | | |
| Recruiting | N/A | 300 | RoW | Testing for chromosomal instability (CIN) | Lei Li | Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Chromosomal Instability, Somatic Copy Number Distortion, Survival Outcomes, Minimal Residual Lesions, Progression-free Survival, Overall Survival | 03/23 | 03/24 | | |
| Recruiting | N/A | 10000 | RoW | | Lei Li | Cervical Cancer, Cervical Intraepithelial Neoplasia, Human Papillomavirus Infection, Cervical Cytology, Cancer Screening | 03/24 | 03/25 | | |
| Recruiting | N/A | 400 | RoW | Testing of homologous recombination deficiency | Lei Li | Epithelial Ovarian Cancer, Homologous Recombination Deficiency, Homologous Recombination Repair Gene Mutation, Poly(ADP-ribose) Polymerase Inhibitor, Drug Resistance, Progression-free Survival, Overall Survival | 03/24 | 03/25 | | |
| Recruiting | N/A | 1000 | RoW | Surgical treatment with and without fertility-sparing procedures, Adjuvant therapy after surgery | Lei Li | Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis), Fertility-sparing Surgery, Survival Outcomes, Fertility Outcomes, Recurrence, Hormone Therapy, Adjuvant Therapy | 03/24 | 03/25 | | |
NCT05522907: Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer |
|
|
| Not yet recruiting | N/A | 1000 | RoW | | First Affiliated Hospital Xi'an Jiaotong University | Prostate Cancer | 12/25 | 12/25 | | |
| Hu, Guang-Yuan |
DIPPER, NCT03427827: PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 450 | RoW | Camrelizumab, SHR-1210 | Sun Yat-sen University | Nasopharyngeal Neoplasms | 02/24 | 02/26 | | |
NCT06749899: QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. |
|
|
| Recruiting | 3 | 580 | RoW | QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy | Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd. | Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | 12/28 | 12/30 | | |
AK104-IIT-019, NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 418 | RoW | Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Akeso Pharmaceuticals, Inc. | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | 01/25 | 01/27 | | |
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 540 | RoW | PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Nasopharyngeal Carcinoma | 05/25 | 05/27 | | |
NCT05979961: Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 454 | RoW | IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy) | Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Zhongshan People's Hospital, Guangdong, China, Wuhan Union Hospital, China, Tongji Hospital, Guangzhou Panyu Central Hospital, Hunan Cancer Hospital, Cancer Hospital of Guizhou Province | Nasopharyngeal Carcinoma | 09/26 | 09/29 | | |
